Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
Celgene has been vilified in the political realm for excessive price increases, which hasn’t helped its stock performance over past year and a half.
You may also be interested in...
Pace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels.
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.